Proprietary technology anchoring modern endogenic practice. Patent pending across compositions of matter, methods of use, formulations, and combinations.
The founding institutional entity holds a proprietary, patent-pending intellectual property estate spanning compositions of matter, methods of use, formulations, and combinations. The estate provides the institutional foundation for the commercial translation of the discipline.
The estate anchors endogenic pharmacology's proprietary technology — specifically, the trade-named bioregulator portfolio u2014 Telogenixu2122, Thymogenixu2122, Vasogenixu2122, Dermogenixu2122, Cortigenixu2122, Lymphogenixu2122, and Gonadogenixu2122 that enables non-injectable bioregulator delivery, the twenty-two-platform delivery technology suite, and the manufacturing methods that produce both — and provides the institutional foundation for the commercial translation of the discipline.
The trade-named peptide-class bioregulators u2014 Telogenixu2122, Thymogenixu2122, Vasogenixu2122, Dermogenixu2122, Cortigenixu2122, Lymphogenixu2122, and Gonadogenixu2122 u2014 each acting on a specific tissue-specific regulatory axis: pineal, vascular, thymic, hepatic, pancreatic, and others.
Therapeutic methods covering indication-specific applications across neurological, immune, vascular, longevity, and metabolic indication areas. Method coverage addresses dosing schedules, route of administration, and indication-specific protocols.
Pharmaceutical formulations enabling non-injectable bioregulator delivery — topical creams and serums, transdermal patches, intranasal sprays, sublingual troches and films, and oral preparations. Formulation coverage spans stability, bioavailability, and delivery-route-specific compositions.
Combination therapeutics pairing bioregulator compounds with co-administered agents — including delivery enhancers, stability adjuvants, and indication-aligned secondary actives — across the OTC opticeutical and Rx endoceutical tiers.
Assignment is held by the founding institutional entity. Licensing inquiries from qualified pharmaceutical, clinical, and research counterparties are directed through the institutional Contact pathway.